Wendy Diller

Senior Writer/Market Analyst

20 Years of Experience

About

Wendy writes on the medical devices and clinical diagnostics sectors, where she focuses on orthopedics/spine, molecular diagnostics and personalized medicine, clinical genomics, womens’ health/ femtech, and reimbursement/commercial strategy and innovation related to these specialties. She welcomes and encourages ideas and input from members of the MedTech Strategist Community.

Her career spans more than 20+ years as a top writer and manager focused on qualitative analysis of the global life sciences industry. She is Chair of Young Women in Bio Metro NY, an organization devoted to encouraging secondary students in the NY area to pursuit STEM careers and on the board of the Columbia Business School of Alumni Club NY

Specialties
Publications
Articles from Wendy Diller:
Read all from this author
Investors & Dealmaking

Assessing Medtech in 2025: Financings Steady in a Weak LifeSci Market

  • 2025-08-08 00:00:00.0
  • Wendy Diller
  • MedTech Strategist

Challenges to biotech financing continue to increase, but medtech financing, already fragile, is holding steady, with interest in cardiovascular and neurotech devices gaining traction in the first half of 2025. More than ever, risk-averse investors favor later-stage companies that have established commercial track records, while they persist in shunning earlier-stage companies, particularly those that are raising money to start their first clinical trials.

Read Article